Zepbound, an injectable weight-loss medication containing tirzepatide, reduces appetite by targeting hormones GLP-1 and GIP, and is FDA-approved for weight loss and sleep apnea in obese adults. A prescription from a licensed healthcare provider is necessary, which can be obtained through in-person or telehealth consultations, and the medication can be filled at pharmacies or clinics. The cost of Zepbound varies significantly based on insurance coverage, with uninsured prices ranging from $349 to $1,000 for a monthly supply, but programs like LillyDirect offer savings. Insurance approval can be complex, requiring prior authorization or trials of other medications, while supply chain issues, previously a problem, are reportedly resolved. Alternatives like Mounjaro contain the same active ingredient for diabetes management, and other GLP-1 medications are available, though Zepbound is unique in its approval for sleep apnea treatment.

Zepbound works by influencing appetite-related hormones GLP-1 and GIP and is approved for adults who are obese or overweight with a weight-related condition, such as type 2 diabetes or heart disease. It should be used alongside a balanced diet and exercise.

A prescription for Zepbound can be obtained through either in-person consultations or telehealth services, where healthcare providers assess medical history and weight goals to determine treatment suitability.

The medication is available in pharmacies or clinics, with options to purchase online from licensed sellers. When buying online, it is crucial to ensure the medication is sealed and not expired, and the FDA's BeSafeRx program offers guidance on safe online purchases.

Cost is a significant barrier for many, with uninsured prices for Zepbound vials and injector pens ranging widely. The LillyDirect program offers cost-saving options for those with a valid prescription, delivering the medication directly to homes.

Insurance coverage can be inconsistent, with some plans requiring steps such as trying other medications first or obtaining prior authorization. It is important to consult with insurance providers to understand coverage specifics.

Supply chain shortages for Zepbound have been resolved according to Eli Lilly, but compounded versions remain discouraged by the FDA due to safety concerns. Alternatives like Mounjaro and other GLP-1 medications are available for those unable to access Zepbound.

Zepbound is the only FDA-approved medication for treating obstructive sleep apnea, making it a unique option for eligible patients seeking treatment for both weight loss and sleep apnea management.